Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | PTAFR | P25105 | 2/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128930 | 1.00 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1DGAT1 | |
| SCHEMBL20120531 | 0.88 | MEN1 (0.35) | MEN1KMT2AKDM4CL3MBTL1DGAT1 | |
| SCHEMBL20129130 | 0.88 | MEN1 (0.35) | MEN1KMT2AKDM4CL3MBTL1DGAT1 | |
| SCHEMBL20128979 | 0.88 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1DGAT1 | |
| SCHEMBL29547526 | 0.88 | MEN1 (0.35) | MEN1KMT2AKDM4CL3MBTL1DGAT1 | |
| SCHEMBL30993048 | 0.86 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1DGAT1 | |
| SCHEMBL21911537 | 0.85 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1DGAT1 | |
| SCHEMBL27098653 | 0.78 | DGAT1 (0.42) | MEN1KMT2AKDM4CDGAT1NPC1 | |
| SCHEMBL20214011 | 0.76 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20129009 | 0.76 | DGAT1 (0.37) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | MEN1 1944/4885KMT2A 1250/4885KDM4C 2111/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | MEN1 1972/4885KMT2A 1074/4885KDM4C 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.